BFRI vs DERM vs PRGO vs NVCR vs GDRX

For growth investors, Biofrontera Inc.

(BFRI) is the stronger pick with 11. 8% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.

4%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.

18β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 87% more volatile than PRGO relative to the S&P 500. On balance sheet safety, GoodRx Holdings, Inc. (GDRX) carries a lower debt/equity ratio of 10% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Biofrontera Inc.

(BFRI) is pulling ahead at 11. 8% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BFRI leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GoodRx Holdings, Inc.

(GDRX) is the more profitable company, earning 3. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 3. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -27. 2% for BFRI. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, PRGO (9.

8% yield) pays a dividend. BFRI, DERM, NVCR, GDRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 9. 8% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BFRI is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; NVCR is a small-cap quality compounder stock; GDRX is a small-cap quality compounder stock. PRGO pays a dividend while BFRI, DERM, NVCR, GDRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.